-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UC25c9ldyJKZ0V2sQ1lAF2HVdPlHdjbzWQvdwee6OgF6c3FQVAw7QYmkXm3n4uUQ LZaGfILQ5qYZIr+vXod7Sg== 0000894579-09-000332.txt : 20090504 0000894579-09-000332.hdr.sgml : 20090504 20090504171230 ACCESSION NUMBER: 0000894579-09-000332 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090504 DATE AS OF CHANGE: 20090504 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: REPROS THERAPEUTICS INC. CENTRAL INDEX KEY: 0000897075 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 760233274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-52909 FILM NUMBER: 09794343 BUSINESS ADDRESS: STREET 1: 2408 TIMBERLOCH PL STREET 2: SUITE B-7 CITY: WOODLANDS STATE: TX ZIP: 77380 BUSINESS PHONE: 2817193400 MAIL ADDRESS: STREET 1: 2408 TIMBERLOCH PLACE B-7 CITY: THE WOODLANDS STATE: TX ZIP: 77380 FORMER COMPANY: FORMER CONFORMED NAME: REPROS THERAPEUTICS INC DATE OF NAME CHANGE: 20060503 FORMER COMPANY: FORMER CONFORMED NAME: ZONAGEN INC DATE OF NAME CHANGE: 19930208 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Vermillion Asset Management LLC CENTRAL INDEX KEY: 0001421758 IRS NUMBER: 202794416 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 267 FIFTH AVENUE STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-683-8816 MAIL ADDRESS: STREET 1: 267 FIFTH AVENUE STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 SC 13G/A 1 vermillion_repros13ga050409.htm SCHEDULE 13G/A - VERMILLION ASSET MANAGEMENT LLC


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



SCHEDULE 13G
(Amendment No. 3)

 Under the Securities Exchange Act of 1934

 

Repros Therapeutics Inc.

(Name of Issuer)
 


 Common Stock

(Title of Class of Securities)

 

76028H100

(CUSIP Number)



 April 14, 2009

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[    ]    Rule 13d-1(b)

[ x ]    Rule 13d-1(c)

[    ]    Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 76028H100

SCHEDULE 13G

Page 2 of 8 Pages

 

1

NAME OF REPORTING PERSON

SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 

Vermillion Asset Management LLC

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP         (a)  [   ]      (b)   [ x ]
 

3

SEC USE ONLY
 

4

CITIZENSHIP OR PLACE OF ORGANIZATION
 

Delaware




NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5

SOLE VOTING POWER
 

0

6

SHARED VOTING POWER
 

0

7

SOLE DISPOSITIVE POWER
 

0

8

SHARED DISPOSITIVE POWER
 

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 

0

10

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 
 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 

0%

12

 TYPE OF REPORTING PERSON

IA

CUSIP No. 76028H100

SCHEDULE 13G

Page 3 of 8 Pages

 

 

 

1

NAME OF REPORTING PERSON

SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

Cyan Opportunities Fund, Ltd.

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP            (a)  [   ]      (b)   [ x ]
 

3

SEC USE ONLY
 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands company





NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5
SOLE VOTING POWER

364,767

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

364,767

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

364,767

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 
 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

2.4%

12

TYPE OF REPORTING PERSON

IA

 

CUSIP No. 76028H100

SCHEDULE 13G

Page 4 of 8 Pages

 

Item 1.

(a).

Name of Issuer: Repros Therapeutics Inc.
 

(b).

Address of Issuer's Principal Executive Offices:

  

 

 

2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380

  

Item 2.

(a).

Name of Person Filing:

  
    i) Vermillion Asset Management, LLC  
    ii) Cyan Opportunities Fund, Ltd.  
 

(b).

Address of Principal Business Office or, if none, Residence:
    i) 267 Fifth Avenue, 7th Floor
New York, NY  10016		  
    ii) c/o Vermillion Asset Management, LLC
267 Fifth Avenue, 7th Floor
New York, New York  10016		  
  (c). Citizenship or Place of Organization:  
    i) Delaware  
    ii) Cayman Islands company  
  (d). Title of Class of Securities:  Common Stock  
  (e). CUSIP Number:  76028H100  

CUSIP No. 76028H100  

Page 5 of 8 Pages

 

Item 3.

If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
 

(a)

[ ]  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
 

(b)

[ ]  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
 

(c)

[ ]  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
 

(d)

[ ]  Investment company registered under section 8 of the Investment Company Act (15 U.S.C. 80a-8);
 

(e)

[ ]  An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E);
 

(f)

[ ]  An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F);
 

(g)

[ ]  A parent holding company or control person in accordance with section 240.13d-1(b)(1)(ii)(G);
 

(h)

[ ]  A savings associations as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 

(i)

[ ]  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 

(j)

[ ]  Group, in accordance with section240.13d-1(b)(1) (ii)(J).
     
  If this statement is filed pursuant to Rule 13D-1(c), check this box.  [ x ]
     

Item 4.

Ownership.
  Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
  VERMILLION ASSET MANAGEMENT, LLC
 

(a).

Amount beneficially owned:  0
  (b). Percent of class:  0%

CUSIP No. 76028H100  

Page 6 of 8 Pages

  (c). Number of shares as to which the person has:
    (1) Sole power to vote or to direct the vote:  0  
    (2) Shared power to vote or to direct the vote:  0  
    (3) Sole power to dispose or to direct the disposition of:  0  
    (4) Shared power to dispose or to direct the disposition of:  0  
    CYAN OPPORTUNITIES FUND, LTD.  
  (a). Amount beneficially owned:  364,767  
  (b). Percent of class:  2.4%  
  (c). Number of shares as to which the person has:  
    (1) Sole power to vote or to direct the vote:  364,767  
    (2) Shared power to vote or to direct the vote:  0  
    (3) Sole power to dispose or to direct the disposition of:  364,767
    (4) Shared power to dispose or to direct the disposition of:  0  
         

Item 5.

Ownership of Five Percent or Less of a Class:
 

0% and 2.4%
   

Item 6.

Ownership of More than Five Percent on Behalf of Another Person:
  Not Applicable

 

 

CUSIP No. 76028H100  

Page 7 of 8 Pages

 

Item 7.

Identification and Classification of Subsidiaries which Acquired the Security Being Reported on by the Parent Holding Company:
 

Not Applicable.

  
     

Item 8.

Identification and Classification of Members of the Group:
 

Not Applicable

  
     

Item 9.

Notice of Dissolution of Group:

  
 

Not Applicable.

  
     

Item 10.

Certification:

  
   

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
 

SIGNATURES
 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 

Date: May 4, 2009

    
       
VERMILLION ASSET MANAGEMENT, LLC
   
By: /s/ Christopher Zuech
  Christopher Zuech, Chief Compliance Officer
   
CYAN OPPORTUNITIES FUND, LTD.
 
By: /s/ Christopher Zuech
  Christopher Zuech, Authorized Signatory
   

CUSIP No. 76028H100  

Page 8 of 8 Pages

 

Joint Filing Agreement

The undersigned hereby agree to the joint filing with each other of a Schedule 13G, and all amendments thereto, with respect to each holding as to which such report must be made, and that each such Schedule and all amendments thereto are made on behalf of each of them.

IN WITNESS WHEREOF, the undersigned hereby execute this agreement this 4th day of May, 2009.

VERMILLION ASSET MANAGEMENT, LLC
   
By: /s/ Christopher Zuech
  Christopher Zuech, Chief Compliance Officer
   
CYAN OPPORTUNITIES FUND, LTD.
 
By: /s/ Christopher Zuech
  Christopher Zuech, Authorized Signatory
   

 

 -----END PRIVACY-ENHANCED MESSAGE-----